AMD

The company's technology allows for ECPs to detect, monitor, and treat AMD 3 years before clinical diagnosis.

A look at the latest developments in retinal disease, including clinical trials and advanced therapies.

Diagnosis highlights overlooked treatments for this disease

Gifted by philanthropist James Grosfeld, the money will fund the launching of a pioneering research initiative as one of the largest investments of resources in the United States.

Researchers found that patients with nAMD lost vision as a result of the lockdown and reduced number of treatments during the COVID-19 pandemic.

Elevatum was created as a phase 4, multicenter, open-label, single-arm trial to specifically study Vabysmo (faricimab-svoa) in these underrepresented populations.

New research finds a drug used to treat alcohol use disorder could be a game-changer in restoring vision for patients with progressive blinding disorders.

Faricimab is now the first and only FDA-approved drug to target two distinct pathways known to cause retinal disease that may lead to vision loss.

Roundtable of experts discuss impact, management of retinal disease.

Practitioners spend more time diagnosing glaucoma or diabetic retinopathy than AMD